Cite
HARVARD Citation
Fan, L. et al. (2022). Advantages of switching to elvitegravir/cobicistat/emtricitabine/tenofovir therapy in virologically-suppressed people living with human immunodeficiency virus/acquired immune deficiency syndrome. Chinese medical journal. 135 (22), pp. 2747-2749. [Online].